AVITA Medical Inc

AVITA Medical, Inc. through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product RECELL system is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company is headquartered in Valencia, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AVITA Medical Inc reports robust Q4 earnings and growth outlook

AVITA Medical's strong financial performance in Q4 2022 and full year 2022, coupled with strategic initiatives and growth projections for 2023, position the company for continued success.
While facing challenges in managing expenses and achieving regulatory approvals, AVITA Medical's focus on innovation, market expansion, and operational efficiency presents opportunities for sustained growth.
Investors should monitor the company's progress in securing PMA approvals, expanding market presence, and optimizing operational costs to capitalize on the projected revenue growth and market opportunities.

AVITA Medical reports robust Q1 earnings, eyes FDA approvals

AVITA Medical Inc. delivered strong financial results in Q1 2023, driven by revenue growth and operational improvements.
The company's strategic priorities for 2023 are on track, with pending FDA applications and new product launches in the pipeline.
While facing challenges in operational transitions and market competition, AVITA Medical remains focused on innovation and growth.

AVITA Medical reports strong Q2 performance with FDA milestones

AVITA Medical had a strong quarter with revenue growth and landmark FDA approvals.
The company faces challenges with increased expenses and supply chain issues.
Opportunities lie in market expansion, new FDA approvals, and international growth strategies.
AVITA Medical aims for realistic growth, focusing on hitting guidance targets to build credibility.

AVITA Medical reports robust revenue growth and strategic international expansion

AVITA Medical Inc's Q3 2023 performance reflects strong revenue growth and strategic initiatives to drive international expansion and profitability by 2025.
The company's focus on core business areas, confidence in growth prospects, and commitment to enhancing patient outcomes position it well for future success.
While facing challenges in pricing strategies and global expansion pace, AVITA Medical is poised to capitalize on opportunities in wound care innovation, regulatory approvals, and international market expansion.

AVITA Medical reports strong earnings, eyes global expansion and profitability

AVITA Medical Inc showcased robust financial performance and strategic advancements in Q4 2023 earnings call.
While facing challenges such as net losses and restructuring, the company is well-positioned for growth.
Opportunities lie in product launches, global expansion, and operational efficiency improvements.
Overall, AVITA Medical's performance and outlook signal a promising trajectory for future success.

AVITA Medical Inc reports Q1 revenue miss, eyes profitability by 2025

AVITA Medical Inc faced challenges in Q1 2024 with revenue falling short of expectations, but the company remains focused on strategic initiatives to drive growth and expand its product portfolio. Despite challenges, AVITA is optimistic about its international expansion efforts and aims to achieve profitability by the third quarter of 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

The company is impacted by staffing issues and the pandemic which hamper growth at the moment, but the shares are already at a 52-week low.

AVITA Medical Is Interesting, But Not Just Yet

Topline data expected in second half of 2022 Topline data expected in second half of 2022

AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 14, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, wishes to advise that its 2021 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held today, December 14, 2021 at 1:00 p.m. Pacific Time (being Wednesday December 15 at 8.00 a.m. Australian Eastern Daylight Time (“AEDT”)), was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

AVITA Medical, Inc. Announces Adjournment of 2021 Annual Stockholder Meeting

VALENCIA, Calif., and MELBOURNE, Australia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences:

AVITA Medical to Present at Upcoming Investor Conferences

AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first fiscal quarter ended September 30, 2021.

AVITA Medical Reports First Fiscal Quarter 2022 Financial Results

AVITA Medical, Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AVITA Medical, Inc. (RCEL) Soars 8%: Is Further Upside Left in the Stock?

Data underscores broad clinical utility and health economic benefits of the RECELL® System Data underscores broad clinical utility and health economic benefits of the RECELL® System

Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn Surgeons

VALENCIA, Calif. and MELBOURNE, Australia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal first quarter 2022 financial results after the market closes on Monday, November 8, 2021. In conjunction with such release, the Company plans to host a conference call and webcast on November 8 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (being 8:30 a.m. Australian Eastern Daylight Time on Tuesday, November 9) to discuss its financial results and recent highlights.

AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results

VALENCIA, Calif., and MELBOURNE, Australia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. Eastern Daylight Time / Tuesday, September 28, 2021 at 6:00 a.m. Australian Eastern Standard Time.

AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference

VALENCIA, Calif., and MELBOURNE, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will participate at the Lake Street 2021 BIG5 Conference on Tuesday, September 14, 2021.

AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference

AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript

VALENCIA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021.

AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results

The FDA has approved AVITA Medical Inc's (NASDAQ:RCEL) request to amend its pivotal trial evaluating RECELL System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design.  The Company will pursue a single cell suspension formulation (1:20 expansion ratio) against the three cell suspensions in the initial trial design.

FDA Approves AVITA Medical Vitiligo Trial With Fewer Participants

VALENCIA, Calif., and MELBOURNE, Australia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal fourth quarter 2021 financial results after the market closes on Thursday, August 26, 2021. In conjunction with such release, the Company plans to host a conference call and webcast on August 26 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (being 6:30 a.m. Australian Eastern Standard Time on Friday, August 27) to discuss its financial results and recent highlights.

AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, June 29, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced that as part of the annual reconstitution of the Russell stock indexes, AVITA Medical has been added to the Russell 3000® Index effective June 28, 2021.

AVITA Medical Announces Inclusion in the Russell 3000 Index

The stock price of AVITA Medical Inc (NASDAQ: RCEL) increased by over 19% pre-market. This is why it happened.

RCEL Stock Price Increases Over 19% Pre-Market: Why It Happened

VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021.

AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results

The RECELL system gained FDA approval for pediatric and large surface area burns.

AVITA Medical Gains FDA Expanded Labels In 'Better Mousetrap' Burn Treatment

Expanded indication for use includes RECELL System for treatment of full-thickness acute burn wounds of all sizes in pediatric and adult patients Expanded indication for use includes RECELL System for treatment of full-thickness acute burn wounds of all sizes in pediatric and adult patients

U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021.

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

Avita shareholders' indecisive earnings reaction provided an excellent buying opportunity. The company's pivotal trial delays are disappointing.

AVITA: Recell's Growing Upside

AVITA Medical's (RCEL) CEO Mike Perry on Q3 2021 Results - Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its third quarter of fiscal year 2021, ended March 31, 2021.

AVITA Medical Reports Third Quarter 2021 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, April 29, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal third quarter 2021 financial results after the market closes on Thursday, May 13, 2021. In conjunction with the release, the Company plans to host a conference call and webcast on May 13th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (being 6:30am Australian Eastern Daylight Time on Friday, May 14) to discuss its financial results and recent highlights.

News for AVITA Medical Inc Stock (RCEL)